It has been reported that radiation therapy followed by PCV chemotherapy (procarbazine, lomustine and vincristine) could improve progression-free survival (PFS) and overall survival (OS) in patients with high-risk WHO grade 2 gliomas after surgery. However, procarbazine is not available in China. In clinical practice, Chinese doctors often use radiotherapy combined with temozolomide to treat these patients, though large-scale prospective studies are lacking. This trial aims to confirm whether RT combined with temozolomide can improve PFS and OS in patients with high-risk low-grade gliomas.
Newly diagnosed supratentorial WHO grade II gliomas;
Aged 18 to 39 years without total resection, or aged 40 to 70 years with any extent of resection or biopsy;
Karnofsky performance score (KPS) ≥ 60;
No more than moderate neurologic symptoms and signs;
WHO grade I gliomas or high-grade gliomas according to WHO's grading system;
Have received prior radiation therapy to the head and neck region;
Have received prior chemotherapy;
Synchronous multiple primary malignant tumor excluding carcinoma of the cervix in situ or nonmelanomatous skin cancer;